Advertisement

Breast Cancer Research and Treatment

, Volume 164, Issue 1, pp 179–187 | Cite as

Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study

  • Noemí Cerulla
  • Àngels Arcusa
  • José-Blas Navarro
  • Maite Garolera
  • Cristina Enero
  • Glòria Chico
  • Luís Fernández-Morales
Epidemiology

Abstract

Purpose

The aim of this study is to elucidate the role of taxanes on cognition when they are administered as a part of the treatment with a fluorouracil, epirubicin and cyclophosphamide (FEC) regimen for breast cancer (BC).

Methods

Two groups of women (n = 51) with a novel diagnostic of BC that were treated with a combination of FEC alone (6 cycles of FEC) or with taxanes (4 cycles of FEC plus 8 cycles of taxanes) were compared at three moments: before chemotherapy, after its completion (short-term evaluation) and at a mean of 74.5 weeks from baseline as a long-term evaluation.

Results

Both groups showed worsening in tests of attention and executive functions on the short-term assessment, with the group treated with taxanes showing more number of affected cognitive measures at this time point, including verbal learning and speed measures. At the long-term evaluation, cognitive dysfunction was still found in attention and executive functions in both groups.

Conclusion

Our results suggest that chemotherapy for BC with a FEC regimen can have a negative effect on cognition. Acute deficits seem to be larger when taxanes are added, but treatment seems to affect cognition also at long term.

Keywords

Breast cancer Oncology Cognition Practice effect Taxanes 

Notes

Acknowledgements

The authors would like to thank the women who participated in the study, and Carme Civit, Carme Aracil, Natalia Cuenca, Nuria de la Osa Chaparro, Carme Pérez-Ventana, Antonio Sánchez-Hidalgo, Resident Intern Psychologists (PIR) from Consorci Sanitari de Terrassa for their contribution.

Funding

The research support was provided by grants from the first prize of the Joan Costa I Roma Foundation (FJCR), Consorci Sanitari de Terrassa, a non-profit organization for research and innovation. None of the authors have financial relationship with the organization that sponsored the research.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

This study complies with the current laws of the country where it was performed.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20(2):485–493CrossRefPubMedGoogle Scholar
  2. 2.
    Hurria A, Somlo G, Ahles T (2007) Renaming ‘chemobrain’. Cancer Invest 25(6):373–377CrossRefPubMedGoogle Scholar
  3. 3.
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292–2299CrossRefPubMedGoogle Scholar
  4. 4.
    Ganz P (1998) Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? J Natl Cancer Inst 90(3):182–183CrossRefPubMedGoogle Scholar
  5. 5.
    Oxman TE, Silverfarb PM (1980) Serial cognitive testing in cancer patients receiving chemotherapy. Am J Psychiatry 137(10):1263–1265CrossRefPubMedGoogle Scholar
  6. 6.
    Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703–708CrossRefPubMedGoogle Scholar
  7. 7.
    Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T (2013) A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39(3):297–304CrossRefPubMedGoogle Scholar
  8. 8.
    Phillips K-A, Bernhard J (2003) Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 95(3):190–197CrossRefPubMedGoogle Scholar
  9. 9.
    Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA (2011) A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19(10):1647–1656CrossRefPubMedGoogle Scholar
  10. 10.
    Van Der Veldt AAM, Hendrikse NH, Smit EF, Mooijer MPJ, Rijnders AY, Gerritsen WR et al (2010) Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging 37(10):1950–1958CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR (2011) An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 38(3):431–438CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Fardell JE, Vardy J, Johnston IN (2013) The short and long term effects of docetaxel chemotherapy on rodent object recognition and spatial reference memory. Life Sci 93(17):596–604CrossRefPubMedGoogle Scholar
  13. 13.
    Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356CrossRefPubMedGoogle Scholar
  14. 14.
    Jim H (2012) Long-term effects of chemo on the cognitive function of cancer patients. Oncology 26:1012–1014PubMedGoogle Scholar
  15. 15.
    Pena-Casanova J, Blesa R, Aguilar M, Gramunt-Fombuena N, Gomez-Anson B, Oliva R et al (2009) Spanish multicenter normative studies (NEURONORMA Project): methods and sample characteristics. Arch Clin Neuropsychol 24(4):307–319CrossRefPubMedGoogle Scholar
  16. 16.
    Vearncombe KJ, Pachana NA (2009) Is cognitive functioning detrimentally affected after early, induced menopause? Menopause 16(1):188–198CrossRefPubMedGoogle Scholar
  17. 17.
    Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H (2010) Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 11(1):118CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109(9):1905–1913CrossRefPubMedGoogle Scholar
  19. 19.
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4(6):561–571CrossRefPubMedGoogle Scholar
  20. 20.
    Spielberger CD, Gorsuch RC, Lushene RE, Vagg PR, Jacobs GA (1983) Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo AltoGoogle Scholar
  21. 21.
    Heaton RK, Grant I, Mathews CG (1991) Comprehensive norms for an expanded halstead-reitan battery: demographic corrections, research findings and clinical applications. Psychological Assessments Resources, Inc., FloridaGoogle Scholar
  22. 22.
    Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D (2005) The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast 14(2):142–150CrossRefPubMedGoogle Scholar
  23. 23.
    Schagen SB, Van Dam FSAM (2006) Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect? [1]. J Clin Oncol 24(32):5170–5171CrossRefPubMedGoogle Scholar
  24. 24.
    Myers JS (2013) Cancer- and chemotherapy-related cognitive changes: the patient experience. Semin Oncol Nurs 29(4):300–307CrossRefPubMedGoogle Scholar
  25. 25.
    Shilling V, Jenkins V, Fallowfield L, Howell T (2003) The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 86:405–412CrossRefPubMedGoogle Scholar
  26. 26.
    Ono M, Ogilvie JM, Wilson JS, Green HJ, Chambers SK, Ownsworth T et al (2015) A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Front Oncol 5:19CrossRefGoogle Scholar
  27. 27.
    Mandilaras V, Wan-Chow-Wah D, Monette J, Gaba F, Monette M, Alfonso L (2013) The impact of cancer therapy on cognition in the elderly. Front Pharmacol 4:48CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bower JE (2008) Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol 26(5):768–777CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Schagen SB, Muller MJ, Boogerd W, van Dam FSAM (2002) Cognitive disfunction and chemotherapy: neuropsychological findings in perspective. Clin Breast Cancer 3(3):100–108CrossRefGoogle Scholar
  30. 30.
    Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB (2012) Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 30(10):1080–1086CrossRefPubMedGoogle Scholar
  31. 31.
    Van Dam FSAM, Schagen SB, Muller MJ, Boogerd W, Wall EVD, Droogleever Fortuyn ME et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90(3):210–218CrossRefPubMedGoogle Scholar
  32. 32.
    Chan RJ, Mccarthy AL, Devenish J, Sullivan KA, Chan A (2015) Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Eur J Cancer 51(4):437–450CrossRefPubMedGoogle Scholar
  33. 33.
    Fardell JE, Vardy J, Johnston IN, Winocur G (2011) Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther 90(3):366–376CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Memory UnitConsorci Sanitari de Terrassa (CST)TerrassaSpain
  2. 2.Brain, Cognition and Behaviour Research GroupUnitat d’Investigació Biomèdica UAB-CST (UIB)TerrassaSpain
  3. 3.Department of Clinical and Health PsychologyUniversitat Autònoma de Barcelona (UAB)Cerdanyola Del VallèsSpain
  4. 4.Department of OncologyConsorci Sanitari de Terrassa (CST)TerrassaSpain
  5. 5.Department of Psychobiology and Methodology of Behavioural SciencesUniversitat Autònoma de Barcelona (UAB)Cerdanyola Del VallèsSpain
  6. 6.Department of Mental HealthConsorci Sanitari de Terrassa (CST)TerrassaSpain
  7. 7.Department of OncologyCorporació Sanitària Parc TaulíSabadellSpain

Personalised recommendations